0001104659-16-159830.txt : 20161130 0001104659-16-159830.hdr.sgml : 20161130 20161130195219 ACCESSION NUMBER: 0001104659-16-159830 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161129 FILED AS OF DATE: 20161130 DATE AS OF CHANGE: 20161130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 500-7867 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chan Barbara Y CENTRAL INDEX KEY: 0001676343 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34921 FILM NUMBER: 162026514 MAIL ADDRESS: STREET 1: C/O AEGERION PHARMACEUTICALS INC. STREET 2: ONE MAIN ST., SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 a4.xml 4 X0306 4 2016-11-29 1 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001676343 Chan Barbara Y C/O AEGERION PHARMACEUTICALS, INC. ONE MAIN STREET, SUITE 800 CAMBRIDGE MA 02142 0 1 0 0 VP, Chief Accounting Officer Stock Option (Right to Buy) 1.58 2016-11-29 4 D 0 26000 D 2026-07-01 Common Stock 26000 0 D 25% of the shares of common stock underlying this stock option award were to vest on July 1, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through July 1, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, the option to purchase common stock of the Issuer was exchanged for an option to purchase 26,665 common shares of Novelion Therapeutics Inc. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." /s/ Jennifer Fitzpatrick, Attorney-in-fact 2016-11-30